TOP TIERMARKET NEWSWIRE

News & sentiment

IMMUNOVANT INC (IMVT) — News & AI sentiment

IMMUNOVANT INC (IMVT) news roundup. 4 stories aggregated over the last 30 days. Average 30-day sentiment is 44/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 9 sales totalling $923K — net selling of $923K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

4

avg sentiment 44/100

Insider net (90d)

$923K

0 buys · 9 sells

Congress (90d)

0

0 buys · 0 sells

IMVT news in the last 24 hours, 7 days, 30 days and 90 days

How much IMVT coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	IMVT stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	4	44/100	IMVT headlines →
Last 90 days	25	39.9/100	IMVT headlines →

Latest stories on IMVT

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

GlobeNewswire50 · neutralgeneral

Oct 21

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

Business Insider50 · neutralgeneral

Oct 21

Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive Threats

Seeking Alpha42 · neutralanalyst

Oct 20

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

PR Newswire34 · bearishgeneral

Oct 12

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Stocktwits News32 · bearishgeneral

Oct 8

Immunovant down after Argenx study fails in Sjogren’s disease

The Fly32 · bearishearnings

Oct 8

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

PR Newswire28 · bearishgeneral

Sep 25

Immunovant stock rating maintained at Buy by H.C. Wainwright

Investing.com Analyst Ratings61 · neutralanalyst

Sep 24

Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program

Barron's28 · bearishproduct/pr

Sep 23

Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback

The Fly48 · neutralgeneral

Sep 23

Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint

MarketWatch28 · bearishproduct/pr

Sep 23

Why is Immunovant stock sliding today?

Investing.com Markets42 · neutralgeneral

Sep 23

Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows

Stocktwits News28 · bearishproduct/pr

Sep 23

Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint

InvestorsHub34 · bearishearnings

Sep 23

Immunovant to Halt IMVT-1402 in Cutaneous Lupus After 57-Patient Study Misses Primary CLASI-A Endpoint September 23, 2026

MarketChameleon28 · bearishproduct/pr

Sep 23

Immunovant announces IMVT-1402 study did not achieve statistical significance

The Fly34 · bearishgeneral

Sep 23

Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy

Seeking Alpha28 · bearishproduct/pr

Sep 23

Immunovant stock falls after lupus drug trial misses goal

Investing.com Markets32 · bearishproduct/pr

Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

GlobeNewswire34 · bearishproduct/pr

Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Business Insider34 · bearishproduct/pr

Sep 23

Immunovant, Inc. (IMVT) files 8-K

SEC 8-K50 · neutralgeneral

Sep 3

Cantor Fitzgerald reiterates Immunovant stock Overweight rating

Investing.com Analyst Ratings61 · neutralanalyst

Aug 25

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

PR Newswire42 · neutralgeneral

Aug 19

Immunovant (IMVT) Q1 2027 Earnings Call Transcript

The Motley Fool56 · neutralearnings

Aug 13

Immunovant Price Target Raised To 45 From 43 At Bofa

The Fly61 · neutralanalyst

Aug 10

Open IMVT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →